For the last couple of years, I’ve been following the progress of a group of individuals who believe death is humanity’s “core problem.” Put simply, they say death is wrong—for everyone. They’ve even said it’s morally wrong.
They established what they consider a new philosophy, and they called it Vitalism.
Vitalism is more than a philosophy, though—it’s a movement for hardcore longevity enthusiasts who want to make real progress in finding treatments that slow or reverse aging. Not just through scientific advances, but by persuading influential people to support their movement, and by changing laws and policies to open up access to experimental drugs.
And they’re starting to make progress.
Vitalism was founded by Adam Gries and Nathan Cheng—two men who united over their shared desire to find ways to extend human lifespan. I first saw Cheng speak back in 2023, at Zuzalu, a pop-up city in Montenegro for people who were interested in life extension and some other technologies. (It was an interesting experience—you can read more about it here.)
Zuzalu was where Gries and Cheng officially launched Vitalism. But I’ve been closely following the longevity scene since 2022. That journey took me to Switzerland, Honduras, and a compound in Berkeley, California, where like-minded longevity enthusiasts shared their dreams of life extension.
It also took me to Washington, DC, where, last year, supporters of lifespan extension presented politicians including Mehmet Oz, who currently leads the Centers for Medicare & Medicaid Services, with their case for changes to laws and policies.
The journey has been fascinating, and at times weird and even surreal. I’ve heard biohacking stories that ended with smoking legs. I’ve been told about a multi-partner relationship that might be made possible through the cryopreservation—and subsequent reanimation—of a man and the multiple wives he’s had throughout his life. I’ve had people tell me to my face that they consider themselves eugenicists, and that they believe that parents should select IVF embryos for their propensity for a long life.
I’ve seen people draw blood during dinner in an upscale hotel restaurant to test their biological age. I’ve heard wild plans to preserve human consciousness and resurrect it in machines. Others have told me their plans to inject men’s penises with multiple doses of an experimental gene therapy in order to treat erectile dysfunction and ultimately achieve “radical longevity.”
I’ve been shouted at and threatened with legal action. I’ve received barefoot hugs. One interviewee told me I needed Botox. It’s been a ride.
My reporting has also made me realize that the current interest in longevity reaches beyond social media influencers and wellness centers. Longevity clinics are growing in number, and there’s been a glut of documentaries about living longer or even forever.
At the same time, powerful people who influence state laws, giant federal funding budgets, and even national health policy are prioritizing the search for treatments that slow or reverse aging. The longevity community was thrilled when longtime supporter Jim O’Neill was made deputy secretary of health and human services last year. Other members of Trump’s administration, including Oz, have spoken about longevity too. “It seems that now there is the most pro-longevity administration in American history,” Gries told me.
I recently spoke to Alicia Jackson, the new director of ARPA-H. The agency, established in 2022 under Joe Biden’s presidency, funds “breakthrough” biomedical research. And it appears to have a new focus on longevity. Jackson previously founded and led Evernow, a company focused on “health and longevity for every woman.”
“There’s a lot of interesting technologies, but they all kind of come back to the same thing: Could we extend life years?” she told me over a Zoom call a few weeks ago. She added that her agency had “incredible support” from “the very top of HHS.” I asked if she was referring to Jim O’Neill. “Yeah,” she said. She wouldn’t go into the specifics.
Gries is right: There is a lot of support for advances in longevity treatments, and some of it is coming from influential people in positions of power. Perhaps the field really is poised for a breakthrough.
And that’s what makes this field so fascinating to cover. Despite the occasional weirdness.
This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, sign up here.
